Key facts
- Aralez Bio’s last known valuation is $40.5M.
- It has raised $24.0M; the latest was Later Stage VC ($12.0M) in Dec 2024.
- Notable investors include Climate Capital, Activate Global, Fifty Years, Good Growth Capital, Impact Science Ventures — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Aralez Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Aralez Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aralez Bio
Developer of noncanonical amino acids designed to make products sustainably. The company specializes in inventing an enzymatic method for synthesizing noncanonical amino acids (NCAA) also called unusual or unnatural amino acids and the proprietary approach allows NCAA to be synthesized with enantiopurity in a single step, enabling clients to access amino acids that are needed for innovations in pharmaceuticals, agriculture, and functional materials.
- Sector
- Healthcare
- HQ
- San Leandro, CA, United States
- Founded
- 2019
- Employees
- 34
- Website
- aralezbio.com/
- Ownership
- Privately Held (backing)
Aralez Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aralez Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aralez Bio in its N-PORT filings yet. We sweep new filings monthly.